JPRN-jRCT2080220767未知3 期
Efficacy and Long-Term Safety of SK-0403 as Add-on Therapy to Alpha-Glucosidase Inhibitor or Pioglitazone in Patients with Type 2 Diabetes
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Patients with type 2 diabetes who have inadequate glycemic control on alpha-glucosidase inhibitor or pioglitazone therapy
- •HbA1C of >= 6.5%, but < 10.0% measured during the run-in period
排除标准
- •Patients with type 1 diabetes mellitus
- •Patients require insulin or oral antidiabetic drug therapy other than alpha-glucosidase inhibitor or pioglitazone
- •Patients with, or a history of, clinically significant cardiac, renal, hepatic, pulmonary, pancreatic and macrovascular disease
- •Patients have a known allergy or hypersensitivity to alpha-glucosidase inhibitor or pioglitazone
研究者
相似试验
未知
3 期
Efficacy and Long-Term Safety of SK-0403 as Add-on Therapy to Sulfonylurea or Biguanides in Patients With Type 2 DiabetesType 2 Diabetes MellitusJPRN-jRCT2080220755Kowa Co., Ltd.
未知
3 期
Efficacy and Long-Term Safety of SK-0403 as Add-on Therapy to Insulin in Patients with Type 2 DiabetesType 2 diabetesJPRN-jRCT2080222199SANWA KAGAKU KENKYUSHO CO.,LTD.
未知
3 期
Efficacy and Long-Term Safety of SK-0403 as Add-on Therapy to Glinides in Patients with Type 2 DiabetesType 2 diabetesJPRN-jRCT2080222002SANWA KAGAKU KENKYUSHO CO.,LTD.60
未知
3 期
Efficacy and Long-Term Safety of SK-0403 as Monotherapy in Patients with Type 2 DiabetesType 2 Diabetes MellitusJPRN-jRCT2080220750Kowa Co., Ltd.
未知
3 期
A clinical pharmacological study of SK-0403Type 2 diabetes mellitusJPRN-jRCT2080221260SANWA KAGAKU KENKYUSHO CO.,LTD.20